1269667-39-1

Basic information

• Product Name: 4-((2,4-dimethoxybenzyI)amino)thieno[3,2-d]pyrimidine-7-carboxylic acid
• Synonyms: 4-((2,4-dimethoxybenzyI)amino)thieno[3,2-d]pyrimidine-7-carboxylic acid
• CAS NO: 1269667-39-1
• Molecular Weight: 345.379
• Mol File: 1269667-39-1.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: 4-((2,4-dimethoxybenzyI)amino)thieno[3,2-d]pyrimidine-7-carboxylic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 4-((2,4-dimethoxybenzyI)amino)thieno[3,2-d]pyrimidine-7-carboxylic acid(1269667-39-1)
• EPA Substance Registry System: 4-((2,4-dimethoxybenzyI)amino)thieno[3,2-d]pyrimidine-7-carboxylic acid(1269667-39-1)

Safety Data

• Hazardous Substances Data: 1269667-39-1(Hazardous Substances Data)

Upstream product

• 20781-20-8 2,4-Dimethoxybenzylamine 
• 22288-78-4 Methyl 3-aminothiophene-2-carboxylate 
• 124-38-9 carbon dioxide 
• 1527518-20-2 7-bromo-N-(2,4-dimethoxybenzyl)thieno[3,2-d]pyrimidine-4-amine 
• 31169-27-4 7-bromo-4-chlorothieno[3,2-d]pyrimidine 
• 1269667-40-4 methyl 4-((2,4-dimethoxybenzyl)amino)thieno[3,2-d]pyrimidine-7-carboxylate 
• 1246223-44-8 methyl 4-chlorothieno[3,2-d]pyrimidine-7-carboxylate 
• 1269667-38-0 methyl 4-hydroxythieno[3,2-d]pyrimidine-7-carboxylate 
• 31169-25-2 7-bromothieno[3,2-d]pyrimidine-4(3H)-one 
• 16234-10-9 3H-thieno[3,2-d]pyrimidin-4-one 

Downstream Products

• 1269667-82-4 N-(2,6-difluoro-3-(propylsulfonamido)phenyl)-4-(2,4-dimethoxybenzylamino)thieno[3,4-d]pyrymidine-7-carboxamide 

Relevant articles and documents

Identification of BRaf-Sparing Amino-Thienopyrimidines with Potent IRE1α Inhibitory Activity

Amino-quinazoline BRaf kinase inhibitor 2 was identified from a library screen as a modest inhibitor of the unfolded protein response (UPR) regulating potential anticancer target IRE1α. A combination of crystallographic and conformational considerations were used to guide structure-based attenuation of BRaf activity and optimization of IRE1α potency. Quinazoline 6-position modifications were found to provide up to 100-fold improvement in IRE1α cellular potency but were ineffective at reducing BRaf activity. A salt bridge contact with Glu651 in IRE1α was then targeted to build in selectivity over BRaf which instead possesses a histidine in this position (His539). Torsional angle analysis revealed that the quinazoline hinge binder core was ill-suited to accommodate the required conformation to effectively reach Glu651, prompting a change to the thienopyrimidine hinge binder. Resulting analogues such as 25 demonstrated good IRE1α cellular potency and imparted more than 1000-fold decrease in BRaf activity.

RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF

Compounds of Formula I are useful for inhibition of Raf kinases. Methods of using compounds of Formula I and stereoisomers, tautomers, prodrugs and pharmaceutically acceptable salts thereof, for in vitro, in situ, and in vivo diagnosis, prevention or trea